Get started
Author

Famke L. Schneiders

Observed names: F. Schneiders, F. schneiders, F.L. Schneiders, Famke L. Schneiders, Famke L Schneiders, Famke Lorelei Schneiders, Famke Schneiders, Schneiders Famke, Schneiders, F., Schneiders, F. L., Schneiders, F.L., Schneiders, Famke, Schneiders, Famke L
ORCID: 0000-0002-5204-1774
Observed ORCID: 0000-0002-5204-1774
OpenAlex ID: A5018769500
Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
2019 · David A. Palma, Robert Olson, et al. · BMC Cancer · 260
PDF
Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
2020 · Robert Olson, Lindsay Mathews, et al. · BMC Cancer · 121
PDF
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
2010 · Famke L. Schneiders, Rik J. Scheper, et al. · Clinical Immunology · 93
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
2017 · Renée C. G. de Bruin, John P. Veluchamy, et al. · OncoImmunology · 87
PDF
Bispecific antibody platforms for cancer immunotherapy
2014 · Roeland Lameris, Renée C.G. de Bruin, et al. · Critical Reviews in Oncology/Hematology · 82
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
2021 · E.B. Ulas, C. Dickhoff, et al. · ESMO Open · 72
Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation
2015 · Berbel J.R. Sluijter, Mari F.C.M. van den Hout, et al. · Cancer Immunology Research · 67
Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up
2012 · Famke L. Schneiders, Renée C.G. de Bruin, et al. · Journal of Clinical Oncology · 62
Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing
2023 · Ymke van der Pol, Normastuti Adhini Tantyo, et al. · EMBO Molecular Medicine · 57
PDF
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
2020 · Chris Dickhoff, Suresh Senan, et al. · BMC Cancer · 39
PDF
Same-day consultation, simulation and lung Stereotactic Ablative Radiotherapy delivery on a Magnetic Resonance-linac
2022 · Miguel A. Palacios, Sonja Verheijen, et al. · Physics and Imaging in Radiation Oncology · 27
PDF
CD1d-Restricted Antigen Presentation by Vγ9Vδ2-T Cells Requires Trogocytosis
2014 · Famke L. Schneiders, Jan Prodöhl, et al. · Cancer Immunology Research · 23
mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells
2015 · Charlotte M Huijts, Famke L Schneiders, et al. · The Journal of Immunology · 22
PDF
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
2024 · Idris Bahce, Chris Dickhoff, et al. · Journal for ImmunoTherapy of Cancer · 19
PDF
Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy
2021 · Hanbo Chen, Famke L. Schneiders, et al. · Radiotherapy and Oncology · 18
Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α
2011 · Famke L. Schneiders, Renée C.G. de Bruin, et al. · Clinical Immunology · 17
Developments in radiation techniques for thoracic malignancies
2021 · Tobias Finazzi, Famke L. Schneiders, et al. · European Respiratory Review · 15
PDF
Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period
2022 · Claire van Vliet, Chris Dickhoff, et al. · Radiotherapy and Oncology · 14
PDF
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol
2024 · David A. Palma, Meredith E. Giuliani, et al. · BMC Palliative Care · 13
PDF
Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy
2023 · Hilâl Tekatli, Miguel A. Palacios, et al. · Radiotherapy and Oncology · 12
PDF
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer
2022 · Rachel E. Sanborn, Famke L. Schneiders, et al. · American Society of Clinical Oncology Educational Book · 11
PDF
Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases
2020 · John R. van Sörnsen de Koste, Miguel A. Palacios, et al. · Radiotherapy and Oncology · 10
PDF
Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC
2026 · Peter S.N. van Rossum, Pim J.J. Damen, et al. · International Journal of Radiation Oncology*Biology*Physics · 9
Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights
2024 · Aurélie De Bruycker, Famke Schneiders, et al. · Lung Cancer · 9
OA06.04 Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial
2023 · C. Dickhoff, D. Heineman, et al. · Journal of Thoracic Oncology · 9
PDF
Works count: 122
Citation count: 1,281
H-index: 16
I10-index: 22
Year
Topic
Type